



Središnja medicinska knjižnica

Zibar K., Knežević Ćuća J., Blaslov K., Bulum T., Smirčić-Duvnjak L.
(2015) *Difference in glucagon-like peptide-1 concentrations between C-peptide negative type 1 diabetes mellitus patients and healthy controls.* Annals of Clinical Biochemistry, 52 (2). pp. 220-5. ISSN 0004-5632

<http://acb.sagepub.com>

<http://dx.doi.org/10.1177/0004563214544709>

<http://medlib.mef.hr/2412>

University of Zagreb Medical School Repository

<http://medlib.mef.hr/>

Difference in glucagon like peptide-1 concentrations between C-peptide negative type 1 diabetic mellitus patients and healthy controls

Karin Zibar¹, Jadranka Knežević Čuča², Kristina Blaslov¹, Tomislav Bulum¹ and Lea Smirčić-Duvnjak^{1,3}

¹Department of Endocrinology and Metabolic Diseases, Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia; ²Department of Clinical Chemistry and Laboratory medicine, Merkur University Hospital, Zagreb, Croatia; ³Medical School University of Zagreb, Zagreb, Croatia

Corresponding author: Karin Zibar, Department of Endocrinology and Metabolic Diseases, Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Dugi Dol 4a, Zagreb 10000, Croatia; tel.: 091 171 01 95, e-mail: karinzibar@gmail.com.

Competing interests

The authors fully declare that there was not any financial or other potential conflict of interest.

Funding

The work was supported by Ministry of Science, Education and Sports of the Republic of Croatia Grant 045-1080230-0516.

Ethical approval

Ethical approval was obtained from Hospital and Medical Faculty Ethical Committee in Zagreb (REF number: 643-03-01-12).

Guarantor

KZ.

Contributorship

All the authors declare that they participated in the acquisition of data, analysis and interpretation of the data, and drafting of the manuscript, and that they have seen and approved the final version.

Acknowledgements

The authors would like to acknowledge to laboratory staff at Merkur University Hospital, Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Zagreb, Croatia.

Abstract

BACKGROUND: The role of glucagon like peptide-1 (GLP-1) has become a new scientific interest in the field of pathophysiology of type 1 diabetes mellitus (T1DM), but the results of the published studies were not uniform. Following that observation, the aim of our study was to measure fasting and postprandial GLP-1 concentrations in T1DM patients and in healthy controls and to examine the difference in those concentrations between the two groups of subjects.

METHODS: The cross-sectional study included 30 C-peptide negative T1DM patients, median age 37 years (20-59), the disease duration 22 years (3-45), and 10 healthy controls, median age 30 years (27-47). Fasting and postprandial total and active GLP-1 concentrations were measured by ELISA (ALPCO, USA). The data were statistically analyzed by SPSS and significance level was accepted at $P < 0.05$.

RESULTS: Both fasting total and active GLP-1 concentrations were significantly lower in T1DM patients (total 0.4 pmol/L, 0-6.4, and active 0.2 pmol/L, 0-1.9) compared with healthy controls (total 3.23 pmol/L, 0.2-5.5, and active 0.8 pmol/L, 0.2-3.6), $P = 0.008$ for total GLP-1, $P = 0.001$ for active GLP-1. After adjustment for age, sex and body mass index, binary logistic regression showed that both fasting total and active GLP-1 remained significantly independently lower in T1DM patients (total GLP-1: OR 2.43, 95%CI 1.203-4.909 and active GLP-1: OR 8.73, 95%CI 1.472-51.787).

CONCLUSIONS: T1DM patients had independently lower the total and active GLP-1 fasting concentrations in comparison with healthy people that supports potential therapeutic role of incretin therapy, along with insulin therapy, in T1DM patients.

Introduction

The new therapeutic approach in type 1 diabetes mellitus (T1DM) grounds on the fact that glucose homeostasis is dependent on common effects of different hormones in addition to insulin, which together contribute to better glucoregulation and less side effects. The role of glucagon like peptide-1 (GLP-1) has become a focus of the scientific interest in the field of pathophysiology of T1DM, but the results of the published studies were unequal. Few smaller studies showed promising therapeutic effect of GLP-1 analogues in T1DM patients so far,^{1, 2-5} while some studies did not find beneficial effect of GLP-1 analogues in T1DM.⁶

The results of published studies showed not only the lower but also the equal fasting GLP-1 concentration in T1DM patients in comparison with non-diabetic population.^{7, 8} Impaired postprandial rise in GLP-1 was described in T1DM patients,⁹ explained by insulin resistance, chronic hyperglycemia and insulin deficiency.⁷ However, certain studies indicated equal postprandial GLP-1 concentration in T1DM patients as in healthy subjects.^{8, 10} The results from Greenbaum *et al.* indicated equal basal and postprandial GLP-1 concentration in T1DM and in healthy people, but impaired incretin effect, due to β -cell destruction.¹¹ On the other hand, Kielgast *et al.* described equal incretin effect in T1DM and in healthy controls and equal fasting GLP-1 concentrations.¹²

Since GLP-1 showed positive antihyperglycemic effect in diabetes mellitus, which is still insufficient examined in T1DM patients, and controversies still exists regarded GLP-1 concentration in T1DM in relation to healthy subjects, the aim of the study was to measure fasting and postprandial GLP-1 concentrations in T1DM patients and in healthy controls and to examine the difference in those concentrations between the two groups of subjects. The secondary aim of the study was to investigate whether there was a gender difference in the examined hormone.

Materials and Methods

Study Population

The cross-sectional study included 30 C-peptide negative T1DM patients and 10 healthy volunteer controls. The sample size was in accordance with the G-power 3.1.3. Calculation for a difference between 2 independent groups (t-test; total sample size 12, $\alpha=0.05$, $1-\beta=0.88$, effect size $d=2.31$, allocation ratio N_2/N_1 0.3). The patients were selected from the annual review at Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Zagreb, Croatia. The diagnosis of T1DM was defined according to the following criteria: less than 40 years at the time of the disease development, episode of diabetic ketoacidosis, positive autoimmune markers and continuous need for insulin therapy within 1 year of the diagnosis.¹³ Inclusion criteria for the T1DM patients were 18-65 years of age, at least 1-year duration of T1DM, without history of cardiovascular, severe liver or chronic kidney disease, with glomerular filtration rate $> 45 \text{ mlmin}^{-1}1.73^{-1}\text{m}^2$ and without adrenal insufficiency. The patients received intensive insulin therapy (long-acting insulin in one or two dosage and ultrashort-acting insulin three times daily) and took no other medication that could affect glucose metabolism. Ten age, gender and body mass index (BMI) matched people were included as the healthy control group (without diabetes mellitus, without history of cardiovascular, severe liver or chronic kidney disease, with glomerular filtration rate $> 45 \text{ mlmin}^{-1}1.73^{-1}\text{m}^2$ and without adrenal insufficiency). The Hospital and Medical Faculty Ethical Committee approved the study protocol. Written informed consent was obtained from each examinee, and the study was performed in accordance with the Declaration of Helsinki.

Detailed medical history, including age at diabetes diagnosis, type of insulin therapy and other medications were obtained. Physical examination included measuring the body weight, height and waist to hip ratio, and calculation of BMI. All investigations were performed in the morning, following an overnight fast. All patients received long-acting insulin the night before and ultrashort-acting insulin before the breakfast. Fasting venous blood samples were drawn at 8:00 h and postprandial 30 minutes after the standard diabetic breakfast in T1DM and in healthy subjects. The

caloric amount of the meal depended on the patient's weight and consisted of 70% carbohydrates, 25% proteins and 5% fat. All healthy control subjects had also standardized breakfast. Venous blood samples (plasma and serum) were collected for biochemistry panel measurement, glycosylated hemoglobin (HbA1c), fasting and postprandial total GLP-1 (GLP-1 0' and GLP-1 30') and active GLP-1 (GLP-1 0' and GLP-1 30') concentration. Plasma samples for GLP-1 were collected in BD™ P700 Blood Collection System for Plasma GLP-1 Preservation (BD Customer Service, USA). All samples were adequately stored from the collection time until analysis on -70 C.

Laboratory Assays

Biochemistry panel, C-peptide, HbA1c, pancreatic islet cell antibodies and serum creatinine concentration were assayed using routine laboratory methods. Serum creatinine (spectrophotometry, OLYMPUS AU400), C-peptide (chemiluminescence, ADVIA Centaur XP), HbA1c in whole blood (immunoturbidimetry -TINIA, COBAS INTEGRA), glutamic acid decarboxylase (GAD), tyrosine phosphatase-related islet antigen 2 (IA-2), (enzyme-linked immunosorbent assay (ELISA); photometer STATFAX 2100), islet cell antibodies (ICA) (indirect immunofluorescence on microscope). Plasma total GLP-1 and active GLP-1 concentrations were measured using ELISA (sandwich) commercial kit, Human Total GLP-1 (7-36&9-36) ELISA Kit, ALPCO, USA; Human Active GLP-1 (7-36) ELISA Kit, ALPCO, USA; photometer STATFAX 2100. Postprandial change in hormone concentration was calculated as difference between postprandial and fasting hormone concentration, expressed as delta (Δ).

Statistical Analysis

Statistical analysis was done using Statistical Package for the Social Sciences (SPSS) ver. 17.0 for Windows. Because of small sample size variables were described as median and minimum-maximum range and nonparametric statistical tests were used. Nominal variables were presented as frequencies. The difference between two independent numerical variables was tested using Mann-Whitney test. Binary logistic regression analysis was used (Hosmer-Leveshow goodness-of-fit test), using OR with 95% CI. Significant level was accepted at $P < 0.05$.

Results

Subject Demographics

Study included 30 C-peptide negative T1DM patients and 10 healthy controls. There were 17 male and 13 female patients, ranging in age from 20 to 59 years (median 37), with median diabetes duration of 22 years (3-45), BMI of 24 kgm⁻² (20-30), HbA1c level of 7.2 % (5.1-12.4), fasting glucose concentration of 6.9 mmol/L (2.5-13.1), postprandial glucose concentration of 10.2 mmol/L (2.7-16.3), median total insulin requirement of 0.6 IUkg⁻¹day⁻¹ (0.32-0.94) and median creatininemia of 66 µmol/L (43-88). According to the number of positive pancreatic islet cell antibodies, four did not have positive antibodies, six had 1 positive antibody, 14 had 2 positive antibodies and six patients had 3 positive antibodies. Healthy controls included 4 males and 6 females, median age of 30 years (27-47), BMI of 25 kgm⁻², median HbA1c level of 5.2 % (4.3-5.8) and median creatininemia of 70 µmol/L (43-114). There was no difference in age ($z=-0.907$, $P=0.365$), gender ($\chi^2=0.533$, $P=0.716$) and BMI ($z=-0.395$, $P=0.693$) between the T1DM patients and healthy controls.

Hormone Levels

Table 1 shows fasting and postprandial total and active GLP-1 concentrations in T1DM patients and healthy controls. Total and active GLP-1 concentrations at 0' were significantly lower in T1DM patients compared with healthy controls, $P=0.008$ and $P=0.001$, respectively. There were no significant differences in total and active GLP-1 concentrations at 30' neither in their postprandial change (Δ GLP-1) between T1DM patients and healthy controls.

Using the multivariate binary logistic regression analysis (Table 2) total and active GLP-1 concentrations at 0' remained independently higher in healthy controls in the crude model, and remained significantly independently higher after adjustment for age, sex and BMI (total GLP-1 0'-OR 2.43, 95%CI 1.203-4.909 and active GLP-1 0'-OR 8.73, 95% CI 1.472-51.787).

There was no difference in GLP-1 concentrations between the groups of patients with T1DM according to the calorie intake and also to the total number of positive pancreatic islet cell antibodies. There was no correlation between GLP-1 with insulin requirement in T1DM patients (data not shown).

Figure 1 shows total GLP-1 concentrations, at 0', 30' and Δ GLP-1, in T1DM patients in relation to gender. Men had significantly higher total GLP-1 at 0' ($P=0.02$), total GLP-1 at 30' ($P<0.001$) and total Δ GLP-1 ($P=0.012$) concentrations in comparison with women. There was no difference in age, disease duration, HbA1c, insulin requirement, BMI and creatinine level between the genders. Men had significantly higher waist to hip ratio in comparison with women ($z=-2.952$, $P=0.03$). Total GLP-1 30' concentration remained independently higher in men by binary logistic regression after adjustment for waist to hip ratio, disease duration, age and insulin requirement (OR 3.267, 95%CI 1.032-10.343) (data not shown). There was no gender difference in active GLP-1 concentrations in T1DM patients. In healthy controls we did not find difference in GLP-1 concentrations in relation to gender (data not shown).

Discussion

T1DM patients had independently lower fasting both total and active GLP-1, but not the postprandial concentrations, in comparison with healthy subjects. The results are partial in accordance with the results of Vilsbøll *et al.* They also found lower fasting GLP-1 concentration in T1DM patients (N=8) in comparison with healthy controls (N=8) and no postprandial difference. We agree that hypothetically exogenous insulin therapy might have inhibitory effect on GLP-1.⁸ The hypothesis is additionally supported by the results of Lugari *et al.*, who described equal fasting active GLP-1 concentration, without postprandial rise, between T1DM and healthy controls.⁷ They examined 16 T1DM patients, which received long-acting insulin the night before, but did not receive insulin before the breakfast. Thus, bolus insulin therapy in study of Vilsbøll and in our study might explain the lower fasting GLP-1 concentration in T1DM patients, by the already proposed mechanism. Greenbaum *et al.* showed equal fasting and postprandial GLP-1 concentrations between the T1DM patients (N=17) and healthy controls, but their patients had better glucoregulation, were younger and had lower BMI, while

there were no data about insulin therapy.¹⁴ Higher calorie intake was followed by higher postprandial GLP-1 concentration in their study, explained by food induced GLP-1 production. Our study did not confirm the relation, while no difference was found in postprandial GLP-1 concentration in relation to different calorie intake between different subjects, but we did not study different calorie intake among the same subjects; and our patients had smaller percentage of fats (5 %) compared with their subjects (33 %). Maybe the difference in fat content is responsible for that. Food stimulation of GLP-1 thus remains possible.

In both groups (T1DM and healthy controls) of our study we found lower fasting and postprandial GLP-1 concentrations in comparison with previous results. So far, the above mentioned differences in GLP-1 concentrations among T1DM patients and between T1DM patients and healthy controls are explained by different methods of hormone measurement, different patients' characteristics and difference in insulin therapy.¹⁵

We also found the difference in total GLP-1 concentrations between the genders in T1DM patients. Men had significantly higher total GLP-1 at 0', at 30' and higher postprandial change (Δ GLP-1) concentrations in comparison with women. After adjustment for age, disease duration, waist to hip ratio and insulin therapy, postprandial total GLP-1 concentration remained independently higher in men in comparison with women with T1DM. There is no study in T1DM that described GLP-1 concentration in relation to gender. One study in non-diabetic healthy population reported higher GLP-1 concentration in women, explaining by higher body fat percentage in women.¹⁶ We could presume that T1DM men had higher GLP-1 due to higher waist to hip ratio in our study; however, multivariate statistics disproved it. In contrast to T1DM, we did not find gender difference in GLP-1 concentration in healthy controls, but the sample was small for definitive conclusion.

Study strengths and limitations

We included T1DM patients without residual β -cell function (C-peptide negative), therefore our sample is more homogenous and we could eliminate endogenous insulin impact on GLP-1 concentrations. In all subjects we measured total and active GLP-1 concentrations. Total GLP-1

concentration should be better indicator of overall GLP-1 secretion, while active GLP-1 possesses almost all biological effects in body. All subjects were adults, of same race, without significant difference in gender abundance, and all subjects were controlled in one center with standardized therapeutic approach. Thus our results could be considered region specific. It was a cross-sectional study, which restricted the ability to establish causality. We did not measure hormones in duplicates and there were single blood collection. Therefore, we were limited by reliance on the resulted data.

Conclusion

T1DM patients had independently lower the total and active GLP-1 fasting concentrations in comparison with healthy people and that supports potential therapeutic role of incretin therapy, along with insulin therapy, in T1DM patients. For the first time to our knowledge we found the difference in total GLP-1 concentrations between the genders in T1DM patients. Men with T1DM had independently higher total GLP-1 postprandial concentration in comparison with women, while no gender difference existed in healthy controls. Further, larger studies, are needed to confirm the results and clarify roles of GLP-1 in the pathophysiology of T1DM and possible therapeutic effect of GLP-1 analogues.

References

1. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I (7-36) amide in type I diabetic patients. *Diabetes care* 1996;**19**(6):580-6
2. Sheffield CA, Kane MP, Busch RS. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection. *Pharmacotherapy* 2007;**27**(10):1449-55
3. Paisley AN, Savage MW, Wiles PG. Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus. *Diabet Med* 2009;**26**(9):935-8

4. Kuhadiya ND, Malik R, Bellini N, *et al.* Liraglutide as Additional Treatment to Insulin in Obese Patients with Type 1 Diabetes Mellitus. *Endocr Pract* 2013;**27**:1-16
5. Dupre J. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. *Regul Pept* 2005;**128**(2):149-57
6. Garg SK, Moser EG, Bode BW, *et al.* Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. *Endocr Pract* 2013;**19**(1):19-28
7. Lugari R, Dell'Anna C, Ugolotti D, *et al.* Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes. *Horm Metab Res* 2000;**32**(10):424-8
8. Vilsboll T, Krarup T, Sonne J, *et al.* Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. *J Clin Endocrinol Metab* 2003;**88**(6):2706-13
9. Kamoi K, Shinozaki Y, Furukawa K, Sasaki H. Decreased active GLP-1 response following large test meal in patients with type 1 diabetes using bolus insulin analogues. *Endocr J* 2011;**58**(10):905-11
10. Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. *Diabetes care* 2011;**34**(7):1463-8
11. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. *Diabetologia* 1986;**29**(1):46-52
12. Kielgast U, Holst JJ, Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta-cell function. *Diabetes* 2011;**60**(5):1599-607
13. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998;**15**(7):539-53

14. Greenbaum CJ, Prigeon RL, D'Alessio DA. Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. *Diabetes* 2002;**51**(4):951-7
15. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? *Diabetologia* 2011;**54**(1):10-8
16. Adam TC, Westerterp-Plantenga MS. Nutrient-stimulated GLP-1 release in normal-weight men and women. *Horm Metab Res* 2005;**37**(2):111-7




Figure 1 Differences in total glucagon-like peptide 1 (GLP-1) concentrations between the gender in type 1 diabetic mellitus patients (Mann-Whitney test; * $z=-2.33$, $P=0.02$; † $z=-3.71$, $P<0.001$; ‡ $z=-2.51$, $P=0.012$)

Table 1 Differences in GLP-1 concentration between T1DM patients and healthy controls (Mann-Whitney test; median, minimum-maximum)

Variable	T1DM patients (n=30)	Healthy controls (n=10)	<i>z</i>	<i>P</i>
GLP-1 (pmol/L)				
Total				
0'	0.4 (0-6.4)	3.23 (0.2-5.5)	-2.66	0.008
30'	4.4 (0.5-29)	4.1 (1.6-10.9)	-0.125	0.901
Δ 30'-0'	3.5 (-1.9-24.3)	1.7 (0.7-6)	-1.203	0.229
Active				
0'	0.2 (0-1.9)	0.8 (0.2-3.6)	-3.387	0.001
30'	1.25 (0.09-9.7)	1.65 (0.5-6.6)	-1.063	0.288
Δ 30'-0'	0.91 (-0.5-9.3)	0.65 (0.1-3.4)	-0.579	0.563

*GLP-1- glucagone like peptide-1; †T1DM- type 1 diabetes mellitus, ‡Δ30'-0'-postprandial change .

Table 2 Binary logistic regression of fasting total and active GLP-1 in relation to healthy controls (N=40)

Independent variable	Model A	Model B
total GLP-1 0' (pmol/L)	1.493 (1.04-2.145)*	2.43 (1.203-4.909)*
active GLP-1 0' (pmol/L)	4.332 (1.442-13.012)*	8.73 (1.472-51.787)*

* $P < 0.05$; OR (95% CI) from separate models; †GLP-1 0'- fasting glucagone like peptide-1.

Model A: crude. Model B: adjusted for age, sex and body mass index.